Bio‐Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross‐Continental Multicenter Study
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.043736 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Maximilian L Müller und 12 weiteren Autor:innen. Beteiligte Einrichtung: Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin Berlin Germany. Hauptthemen laut MEDLINE: Adrenomedullin, Amyloidosis, Cardiomyopathies. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Bio‐ADM (bioactive adrenomedullin) is a vasoactive peptide hormone that predicts clinical outcomes in heart failure—the main driver of adverse outcomes in cardiac amyloidosis (CA). This prospective observational study sought to assess the prognostic role of bio‐ADM in CA.
Methods
Patients with CA were enrolled from amyloid centers in Germany (observation cohort), Japan, and the United States (combined validation cohort). Bio‐ADM was quantified using the sphingotest bio‐ADM assay. Associations of bio‐ADM with all‐cause death and major adverse cardiovascular events over 2 years were assessed using Kaplan–Meier and Cox regression analyses. Likelihood ratio chi‐square tests for nested models evaluated whether adding bio‐ADM improves validated prognostic staging systems.
Results
In both the German observation cohort (n=86) and the combined validation cohort from Japan and the United States (n=124), elevated bio‐ADM (>29 pg/mL) was associated with more frequent all‐cause death and major adverse cardiovascular events. Bio‐ADM remained independently associated with impaired overall ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin Berlin Germany.
- Department of Cardiology, Angiology, and Intensive Care Medicine Deutsches Herzzentrum der Charité Berlin Germany.
- Amyloidosis Center Charité Berlin (ACCB) Charité-Universitätsmedizin Berlin Berlin Germany.
- Sana Klinikum Lichtenberg, Innere Medizin II: Schwerpunkt Kardiologie Berlin Germany.
- Department of Neurology and Experimental Neurology Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
- Berlin Institute of Health (BIH) at Charité Berlin Germany.
ORCID-Profile: Maximilian L Müller, Katrin Hahn, Janin Schulte, Kaitlin M S Moore, Seiji Takashio, Yasuhiro Izumiya, Joshua D Mitchell, Kenichi Tsujita, Ulf Landmesser, Bettina Heidecker
Zitieren
APA
Müller, M. L., Knebel, F., Hahn, K., Schulte, J., Arlt, B., Hartmann, O., Moore, K. M. S., Takashio, S., Izumiya, Y., Mitchell, J. D., Tsujita, K., Landmesser, U., & Heidecker, B. (2026). Bio‐Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross‐Continental Multicenter Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.043736
Vancouver
Müller ML, Knebel F, Hahn K, Schulte J, Arlt B, Hartmann O, et al. Bio‐Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross‐Continental Multicenter Study. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.043736
BibTeX
@article{Mller2026,
author = {Müller, Maximilian L and Knebel, Fabian and Hahn, Katrin and Schulte, Janin and Arlt, Birte and Hartmann, Oliver and Moore, Kaitlin M S and Takashio, Seiji and Izumiya, Yasuhiro and Mitchell, Joshua D and Tsujita, Kenichi and Landmesser, Ulf and Heidecker, Bettina},
title = {Bio‐Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross‐Continental Multicenter Study},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.043736}
}
EUVIMED